News
Health Secretary Robert F. Kennedy Jr. named eight members to serve on a key panel of vaccine advisers on Wednesday, ...
Health Secretary Robert Kennedy Jr. has replaced all members of the CDC's vaccine advisory panel with a group that includes ...
Goldman Sachs 46th Annual Global Healthcare Conference June 11, 2025 2:00 PM ETCompany ParticipantsJames Patrick Kelly ...
Novavax's combo and standalone flu vaccines showed strong immune responses and good safety in a Phase 3 trial of adults 65 ...
20h
Stocktwits on MSNNovavax’s Covid-Flu Combo, Standalone Flu Vaccines Demonstrate Robust Immune Response In Late-Stage Trial: Retail Says It’s ‘A Very Good Sign’Novavax, Inc. (NVAX) on Wednesday said that its COVID-19-Influenza combination and stand-alone Influenza vaccine candidates ...
Novavax (NVAX) stock gains as the company reports promising Phase 3 trial results for its COVID-19-Influenza combo vaccine and stand-alone flu shot. Read more here.
The NIH halted its policy requiring universities and research institutes to certify they do not have unlawful diversity, ...
The abrupt termination of the 17 panelists guiding the CDC’s vaccine recommendations could yield a new committee more aligned ...
The FDA has approved Nuvaxovid to prevent COVID-19 in adults 65 years and older and high-risk individuals 12 through 64 years.
The U.S. Food and Drug Administration has approved a new lower-dose vaccine for active immunization against COVID-19 caused ...
8d
Zacks Investment Research on MSNModerna Secures FDA Nod for Next-Gen COVID-19 Vaccine mNexspikeModerna MRNA announced the FDA approval for mRNA-1283, its next-generation refrigerator-stable COVID-19 vaccine, though for a ...
The FDA approved Moderna’s lower-dose COVID-19 vaccine, but only for individuals aged 65 years or older and people aged 12 to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results